Why Vertex Is Striking Another Gene-Editing Deal With a Company Not Named CRISPR Therapeutics - NewsBreak Home > Business > Article
2 years ago By Hardik — Vertex is spending $41 million upfront in a collaboration with Mammoth Biosciences. The two companies will develop gene-editing therapies targeting two gen
#vertex #namedcrisprtherapeutics
Vertex Acquires LCR-Dixon to Expand Global Tax Automation Portfolio - NewsBreak Home > Business > Article
3 years ago By Flemming — KING OF PRUSSIA, Pa., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) and its subsidiaries, ("Vertex" or the "Company"), a global provider o
#vertex #expand #portfolio